1. New Perspectives for Your nAMD Patients

3. This program may include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Introduction

5. Undertreatment in Real-World Settings Can Lead to Suboptimal Gains in Vision

6. Real-World Evidence Shows That Over 70% of Patients With nAMD are Undertreated in the First Year of Therapy

7. Observational Study of FRB Database Eyes: Adherence to Treatment May Improve Results

8. The Number of Injections Affects VA Results

9. Objectives of the Treatments

10. Real-World Evidence Highlights the Relationship Between Injection Frequency and VA Gains

11. Sustain Treatment: Adequate and Continued Anti-VEGF Therapy Can Maintain Long-Term Vision in the Real World

12. Emerging Treatments for nAMD

13. Molecular Sizes of Anti-VEGF Agents

14. HAWK and HARRIER Studies: Brolucizumab Reduced Dosing Frequency

15. Patients treated with brolucizumab 6 mg had fewer visits in which  sub-RPE fluid was observed from Week 36 to 48

16. Conbercept for Choroidal Neovascularization Secondary to nAMD: The PHOENIX Study

17. Designed Ankyrin Repeat Protein (DARPin®): Abicipar Pegol

18. Phase 2 Studies Using RG7716

19. OPT-302 in PHASE 2B nAMD

20. HAWK and HARRIER Studies: Brolucizumab Reduced Dosing Frequency

21. HAWK and HARRIER: Study Design

23. Phase 3 CEDAR and SEQUOIA

24. Conbercept for Choroidal Neovascularization Secondary to nAMD: The PHOENIX Study

25. Targeting Key Angiogenic Pathways With RG7716

26. RG7716 in the BOULEVARD Study

27. Phase 2 Studies Using RG7716

28. Phase 1/2a Data of OPT-302 in nAMD

29. Gene Therapy: The Example of RGX-314

30. Conclusions

31. Abbreviations